Daniel Scott Ory, Executive Vice President and Chief Medical Officer of Editas Medicine, Inc., filed a Form 4 on September 9, 2026, disclosing the grant of 950,000 stock options awarded on September 8, 2026.

Key Highlights

  • Reporting person: Daniel Scott Ory, EVP and Chief Medical Officer of Editas Medicine, Inc.
  • Option grant: 950,000 stock options (right to buy Common Stock) granted on September 8, 2026.
  • Exercise price: $3.03 per share, with an expiration date of September 7, 2036.
  • Price paid for derivative security: $0.
  • Vesting schedule: 25% of shares vest on October 15, 2027, with the remaining 75% vesting in equal monthly installments through October 15, 2030.
  • Post-transaction holdings: 950,000 derivative securities beneficially owned directly following the reported transaction.

Stock Option Grant Details for Editas Medicine's Chief Medical Officer

According to the filing, Editas Medicine, Inc. (NASDAQ:EDIT) granted Daniel Scott Ory, the company's EVP and Chief Medical Officer, a stock option to purchase 950,000 shares of Common Stock on September 8, 2026. The option carries an exercise price of $3.03 per share and is set to expire on September 7, 2036. The filing records the price of the derivative security as $0, indicating no cost was paid by the reporting person to receive the grant.

The filing discloses that the option is scheduled to vest over four years. As described in the explanation of responses, "25% of the shares to vest on October 15, 2027 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through October 15, 2030." The transaction is coded as an acquisition (A) in Table II of the filing, covering derivative securities.

Following the reported transaction, Ory beneficially owns 950,000 derivative securities directly, as reported in the filing. No non-derivative securities transactions were reported in Table I. The Form 4 was filed by one reporting person and is not an amendment to a prior filing. The filing was signed by Daniel Ory, M.D., on September 9, 2026.

What Was Disclosed

The filing discloses the grant of 950,000 stock options to Editas Medicine's Chief Medical Officer on September 8, 2026, at an exercise price of $3.03 per share, vesting over four years with expiration on September 7, 2036.